Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 8 | 2022 | 862 | 2.120 |
Why?
|
| Vietnam | 15 | 2024 | 165 | 1.110 |
Why?
|
| Hospitalization | 6 | 2018 | 1290 | 1.020 |
Why?
|
| Hypertension | 6 | 2023 | 568 | 0.930 |
Why?
|
| Patients | 2 | 2021 | 103 | 0.840 |
Why?
|
| Clinical Laboratory Services | 1 | 2021 | 5 | 0.750 |
Why?
|
| Medical Laboratory Personnel | 1 | 2021 | 8 | 0.750 |
Why?
|
| Hospital Mortality | 5 | 2022 | 841 | 0.740 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2022 | 73 | 0.730 |
Why?
|
| Shock, Cardiogenic | 2 | 2022 | 85 | 0.720 |
Why?
|
| Patient Education as Topic | 3 | 2023 | 453 | 0.650 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 441 | 0.590 |
Why?
|
| Sample Size | 1 | 2017 | 61 | 0.560 |
Why?
|
| Hospital Administration | 2 | 2014 | 41 | 0.560 |
Why?
|
| Aged | 20 | 2024 | 13416 | 0.550 |
Why?
|
| Life Style | 1 | 2018 | 299 | 0.540 |
Why?
|
| Forecasting | 1 | 2017 | 219 | 0.520 |
Why?
|
| Healthcare Disparities | 2 | 2010 | 326 | 0.520 |
Why?
|
| Sex Factors | 4 | 2014 | 935 | 0.520 |
Why?
|
| Health Behavior | 1 | 2018 | 451 | 0.490 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 788 | 0.480 |
Why?
|
| Patient Selection | 1 | 2017 | 464 | 0.470 |
Why?
|
| Male | 26 | 2024 | 27739 | 0.450 |
Why?
|
| Developing Countries | 4 | 2023 | 85 | 0.440 |
Why?
|
| Female | 27 | 2024 | 30705 | 0.430 |
Why?
|
| Age Factors | 4 | 2018 | 1504 | 0.420 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2019 | 724 | 0.420 |
Why?
|
| Sex Characteristics | 1 | 2014 | 197 | 0.400 |
Why?
|
| Humans | 40 | 2024 | 59360 | 0.400 |
Why?
|
| Risk Assessment | 2 | 2017 | 1921 | 0.400 |
Why?
|
| Acute Coronary Syndrome | 2 | 2018 | 250 | 0.400 |
Why?
|
| Aedes | 4 | 2016 | 12 | 0.400 |
Why?
|
| Dengue | 4 | 2016 | 92 | 0.390 |
Why?
|
| Dengue Virus | 3 | 2015 | 95 | 0.340 |
Why?
|
| Myocardial Revascularization | 1 | 2010 | 71 | 0.340 |
Why?
|
| Nurses | 2 | 2021 | 102 | 0.330 |
Why?
|
| Middle Aged | 14 | 2022 | 16317 | 0.330 |
Why?
|
| Outpatients | 2 | 2022 | 136 | 0.330 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 98 | 0.320 |
Why?
|
| Noncommunicable Diseases | 2 | 2019 | 15 | 0.320 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 412 | 0.320 |
Why?
|
| Transportation of Patients | 1 | 2009 | 42 | 0.320 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5128 | 0.300 |
Why?
|
| Heart Block | 1 | 2008 | 22 | 0.300 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 442 | 0.300 |
Why?
|
| Inpatients | 1 | 2010 | 291 | 0.290 |
Why?
|
| Prognosis | 4 | 2018 | 1600 | 0.270 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 2337 | 0.250 |
Why?
|
| Incidence | 5 | 2018 | 1237 | 0.250 |
Why?
|
| Adult | 15 | 2023 | 15669 | 0.240 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2009 | 450 | 0.240 |
Why?
|
| Pharmacists | 3 | 2020 | 122 | 0.220 |
Why?
|
| Risk Factors | 6 | 2018 | 4984 | 0.210 |
Why?
|
| Adenoma | 1 | 2023 | 64 | 0.210 |
Why?
|
| Esophagitis | 1 | 2022 | 8 | 0.210 |
Why?
|
| Peptic Ulcer | 1 | 2022 | 20 | 0.200 |
Why?
|
| Coronary Artery Bypass | 2 | 2018 | 274 | 0.200 |
Why?
|
| Pain Measurement | 2 | 2021 | 327 | 0.200 |
Why?
|
| Propofol | 1 | 2022 | 21 | 0.200 |
Why?
|
| Gastroesophageal Reflux | 1 | 2022 | 82 | 0.200 |
Why?
|
| Ketamine | 1 | 2022 | 32 | 0.190 |
Why?
|
| Public Health | 2 | 2021 | 174 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5284 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2023 | 129 | 0.180 |
Why?
|
| Drug Hypersensitivity | 1 | 2021 | 28 | 0.180 |
Why?
|
| Blood Culture | 1 | 2020 | 11 | 0.180 |
Why?
|
| Dementia | 1 | 2024 | 248 | 0.170 |
Why?
|
| Time Factors | 4 | 2018 | 3617 | 0.170 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2513 | 0.170 |
Why?
|
| Frailty | 1 | 2022 | 124 | 0.160 |
Why?
|
| Pharmacy Technicians | 1 | 2019 | 3 | 0.160 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 805 | 0.160 |
Why?
|
| Videotape Recording | 1 | 2019 | 46 | 0.160 |
Why?
|
| Bacteremia | 1 | 2020 | 91 | 0.160 |
Why?
|
| Perception | 1 | 2020 | 167 | 0.160 |
Why?
|
| Computers, Handheld | 1 | 2019 | 38 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 22 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 94 | 0.160 |
Why?
|
| Pandemics | 2 | 2023 | 615 | 0.160 |
Why?
|
| Hospitals | 1 | 2022 | 375 | 0.160 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 31 | 0.160 |
Why?
|
| Massachusetts | 3 | 2017 | 2002 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2021 | 349 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2023 | 3067 | 0.160 |
Why?
|
| Prevalence | 3 | 2022 | 1252 | 0.150 |
Why?
|
| Warfarin | 1 | 2019 | 105 | 0.150 |
Why?
|
| Insect Vectors | 2 | 2015 | 14 | 0.150 |
Why?
|
| Short Bowel Syndrome | 1 | 2018 | 5 | 0.150 |
Why?
|
| Growth | 1 | 2018 | 22 | 0.150 |
Why?
|
| Talaromyces | 1 | 2017 | 1 | 0.150 |
Why?
|
| Itraconazole | 1 | 2017 | 13 | 0.150 |
Why?
|
| Minority Groups | 1 | 2019 | 135 | 0.150 |
Why?
|
| Growth Disorders | 1 | 2018 | 28 | 0.150 |
Why?
|
| Dermatomycoses | 1 | 2017 | 13 | 0.150 |
Why?
|
| Multiple Chronic Conditions | 1 | 2018 | 37 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 677 | 0.140 |
Why?
|
| Rural Population | 1 | 2019 | 185 | 0.140 |
Why?
|
| Poverty | 1 | 2019 | 281 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 192 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 205 | 0.140 |
Why?
|
| Antifungal Agents | 1 | 2017 | 120 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2019 | 239 | 0.140 |
Why?
|
| Child Development | 1 | 2018 | 79 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2017 | 136 | 0.140 |
Why?
|
| Quality of Life | 1 | 2024 | 1137 | 0.130 |
Why?
|
| Mosquito Control | 1 | 2016 | 6 | 0.130 |
Why?
|
| Insect Repellents | 1 | 2016 | 3 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 256 | 0.130 |
Why?
|
| Cause of Death | 1 | 2017 | 210 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 408 | 0.130 |
Why?
|
| Culture | 2 | 2016 | 73 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2019 | 914 | 0.120 |
Why?
|
| Wolbachia | 1 | 2015 | 3 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 456 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2016 | 135 | 0.120 |
Why?
|
| Income | 3 | 2021 | 156 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 84 | 0.110 |
Why?
|
| Health Education | 1 | 2016 | 182 | 0.110 |
Why?
|
| Pain | 3 | 2022 | 396 | 0.110 |
Why?
|
| Viruses | 1 | 2015 | 78 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2015 | 114 | 0.110 |
Why?
|
| Caregivers | 1 | 2016 | 231 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2012 | 745 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6071 | 0.100 |
Why?
|
| Comorbidity | 1 | 2014 | 1078 | 0.090 |
Why?
|
| Smoking Prevention | 1 | 2012 | 158 | 0.090 |
Why?
|
| South America | 1 | 2010 | 23 | 0.090 |
Why?
|
| Physicians | 1 | 2016 | 435 | 0.090 |
Why?
|
| New Zealand | 1 | 2010 | 37 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 25 | 0.090 |
Why?
|
| North America | 1 | 2010 | 106 | 0.090 |
Why?
|
| Australia | 1 | 2010 | 86 | 0.090 |
Why?
|
| Europe | 1 | 2010 | 184 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 142 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 147 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 167 | 0.080 |
Why?
|
| Aspirin | 1 | 2010 | 166 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 452 | 0.080 |
Why?
|
| Young Adult | 5 | 2019 | 4267 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 2 | 2019 | 102 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 1232 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 660 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 211 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 206 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 259 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 297 | 0.070 |
Why?
|
| Registries | 1 | 2010 | 801 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2373 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2012 | 541 | 0.070 |
Why?
|
| Adolescent | 4 | 2020 | 5824 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2010 | 510 | 0.070 |
Why?
|
| Data Collection | 2 | 2019 | 371 | 0.060 |
Why?
|
| Quarantine | 1 | 2023 | 10 | 0.050 |
Why?
|
| Ghana | 1 | 2023 | 10 | 0.050 |
Why?
|
| Cathartics | 1 | 2023 | 8 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 79 | 0.050 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2022 | 20 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2023 | 86 | 0.050 |
Why?
|
| Manometry | 1 | 2022 | 22 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 68 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2018 | 1283 | 0.050 |
Why?
|
| Infant | 2 | 2018 | 1486 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2024 | 289 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2022 | 164 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 74 | 0.050 |
Why?
|
| Fentanyl | 1 | 2022 | 72 | 0.050 |
Why?
|
| Analgesics | 1 | 2022 | 96 | 0.050 |
Why?
|
| Developed Countries | 1 | 2021 | 16 | 0.050 |
Why?
|
| Penicillins | 1 | 2021 | 29 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 76 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 107 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2022 | 159 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 10 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 103 | 0.040 |
Why?
|
| Community Health Workers | 1 | 2020 | 37 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 292 | 0.040 |
Why?
|
| United States | 3 | 2018 | 7390 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 115 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 423 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 166 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 97 | 0.040 |
Why?
|
| Parenteral Nutrition | 1 | 2018 | 21 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2024 | 661 | 0.040 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 54 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2018 | 93 | 0.040 |
Why?
|
| Animals | 4 | 2016 | 19651 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 483 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 470 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1561 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 356 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2016 | 42 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 883 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 802 | 0.030 |
Why?
|
| Disease Vectors | 1 | 2015 | 7 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 20 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 342 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 14 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2015 | 17 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2019 | 477 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 44 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 191 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 416 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 357 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 99 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2015 | 55 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 157 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 735 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 775 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 489 | 0.030 |
Why?
|
| Longevity | 1 | 2015 | 110 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 527 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 256 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 1782 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 396 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 92 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 241 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 146 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 362 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2374 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2202 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 826 | 0.020 |
Why?
|